These forwardlooking statements include statements regarding market opportunities the potential benefits of PPMO including offering greater efficacy with less frequent dosing being a step order improvement over our current PMO platform and profoundly impacting the course of Duchenne our prediction that SRP5051 at 30 mgkg will achieve greater than 10 dystrophin over time with monthly dosing and our plans including to work with great urgency to discuss the results with regulatory agencies and gain their insights including the development path to support an accelerated approval of SRP5051 in the United States and to present full results at a future medical meeting